Pulsed Field or Conventional Thermal Ablation for Paroxysmal Atrial Fibrillation.

Area of Science:

• Cardiology
• Electrophysiology
• Medical Devices

Background:

• Catheter-based pulmonary vein isolation is a standard treatment for paroxysmal atrial fibrillation.
• Pulsed field ablation (PFA) offers a novel approach using electrical fields, potentially sparing non-cardiac tissues.
• Direct comparisons of PFA efficacy and safety against traditional thermal ablation methods are limited.

Purpose of the Study:

• To evaluate the noninferiority of pulsed field ablation compared to conventional thermal ablation (radiofrequency or cryoballoon) for paroxysmal atrial fibrillation.
• To assess both efficacy and safety endpoints in a randomized trial.

Main Methods:

• A randomized, single-blind, noninferiority trial involving 607 patients with drug-refractory paroxysmal atrial fibrillation.
• Patients were assigned 1:1 to undergo either pulsed field ablation or conventional thermal ablation.
• Primary efficacy endpoint: freedom from procedural failure, atrial tachyarrhythmia, antiarrhythmic drug use, cardioversion, or repeat ablation at 1 year. Primary safety endpoint: device- and procedure-related serious adverse events.

Main Results:

• At 1 year, 73.3% of patients in the pulsed field ablation group met the primary efficacy endpoint versus 71.3% in the thermal ablation group (noninferiority confirmed).
• The incidence of primary safety endpoint events was 2.1% for pulsed field ablation and 1.5% for thermal ablation (noninferiority confirmed).
• No significant difference was observed in the primary efficacy or safety outcomes between the two ablation methods.

Conclusions:

• Pulsed field ablation is noninferior to conventional thermal ablation for treating paroxysmal atrial fibrillation.
• Both methods demonstrated comparable efficacy and safety profiles at the one-year follow-up.
• PFA represents a viable alternative to thermal ablation in catheter-based treatment for atrial fibrillation.